Skip to content
MarketScale
‹ Back to IndustriesHealthcare

Extending Performance Requires A Collaboration Between Different Disciplines

Joel Totoro’s love for professional sports and health has teed him up for a successful career as Director of Sports Science at Thorne. Totoro noticed that the development of a holistic approach has helped extend careers. Teams now include full-time dieticians, psychologists, physical therapists, and the primary care team. “Using health and wellness can be…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Share

Get featured

Want to get featured in MarketScale Healthcare?

Create a free MarketScale workspace and get your company's expertise featured across our Healthcare coverage. No credit card, no demo required.

Start free

Joel Totoro’s love for professional sports and health has teed him up for a successful career as Director of Sports Science at Thorne. Totoro noticed that the development of a holistic approach has helped extend careers. Teams now include full-time dieticians, psychologists, physical therapists, and the primary care team.

“Using health and wellness can be an enhancer in the game,” Totoro recognizes that extended careers are attributed to “the collaboration between different disciplines, nutrition and metabolic, strength coaches, psychologist, taking care of it [wellbeing] from all aspects.” Health is an interconnected system. We’re shifting and becoming more focused on preventative care, and understandably, Totoro says, “is what healthcare should be.”

Thorne is leading the way in quality and effective supplements. Thorne’s supplements are strictly made with rigorous testing and the best ingredients to ensure high quality. Totoro understands that Thorne is in the “service industry, at the end of the day. We want you to be as healthy as you can be for as long as you can be.” If the product isn’t improving the overall quality of life, it’s not doing its job. “[Thorne is] altruistically driven, and that isn’t [a factor] in other supplement companies,” explains Totoro.

In an industry with a bad rap, supplements tend to be a money-driven business. Thorne is setting the bar high in terms of quality control. Many of Thorne’s supplements are backed by NSF Certified for Sport. They provide peace of mind to professional athletes whose livelihood depends on clean testing before a performance. If a supplement had a filler, which may not be dangerous to an individual, but is considered illegal in a sport, the athlete’s career could be on the line. Thorne’s high standards honor that athletes’ careers depend on reliable products.

Thorne offers personalized, scientific testing and solutions so that individuals can create custom supplement regimens. Totoro explains that Thorne empowers its customers with “individual control and understanding.”

While Thorne’s standards are a huge differentiator, Totoro explains, “what’s really exciting is the fact that we have partners in the medical space.” Recently, Thorne developed a supplement for brain health after a concussion with The Mayo Clinic. The supplement gives the brain the nutrients to support cell growth, ultimately benefitting memory and focus.

From professional athletes to laypeople, Thorne provides the tools for individuals to improve and maintain their health. After all, as Totoro says, “you are the CEO of you,” and you have to “do what’s best for you.”

As the CEO of his health, Totoro’s supplement routine is customized. Magnesium is what introduced him to Thorne. And he’s excited about the development of leucine (found in SynaQuell, which supports cognition and focus) and Theanine (helps modify brain waves by increasing alpha-wave production. It also enhances brain neurotransmitters involved in stress management.)

Eric Dickerson Turns His Toughest Career Moments into Lessons for the Next Generation of Players

How College Athletic Departments Should Be Educating Their Athletes on NIL

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Get your team featuredSee how it works15 minutes, straight to a calendar.
B2B Weekly

The week in Healthcare, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free plan

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale workspace, up to 10 people
One professional video edit a month for qualifying companies
Media requests to your crowd, remote recording, AI writing tools
$0, no credit card, nothing that expires

More Healthcare Insights

NICE recommends Enhertu for HER2-low advanced breast cancer in England

NICE recommends Enhertu for HER2-low advanced breast cancer in England

American Pharmaceutical Review reported that NICE has recommended AstraZeneca and Daiichi Sankyo’s Enhertu for routine NHS use in people with HER2-low advanced breast cancer, following a commercial agreement and updates to NICE’s methods under the U.K.-U.S. Pharmaceutical Pricing Agreement.

  • 01NICE tied the reversal to 2026 changes: higher cost-effectiveness thresholds that took effect in April and a new quality-of-life assessment method published Aug. 27, 2026.
  • 02Access planning still varies by nation: Fierce Pharma reported Wales requires funding within 60 days of final guidance, while Scotland and Northern Ireland follow separate processes.

Sep 21, 2026

Eli Lilly’s $6.5B Houston Bet Highlights U.S. Pharma Reshoring

Eli Lilly’s $6.5B Houston Bet Highlights U.S. Pharma Reshoring

Eli Lilly is investing $6.5 billion in a Houston manufacturing facility set to open around 2030, primarily to scale production of Foundayo, its oral GLP-1 treatment. The project signals a broader shift in U.S. pharmaceutical manufacturing reshoring and underscores the supply chain challenge of forecasting demand and building capacity years in advance for breakthrough therapeutics.

  • 01Eli Lilly commits $6.5 billion to a Houston pharmaceutical manufacturing facility due for completion around 2030, one of the largest single U.S. pharma production investments in recent years
  • 02GLP-1 demand forecasting remains highly uncertain: Lilly's CEO noted that one-third of new GLP-1 pill patients are now choosing Foundayo, illustrating fast-moving market share shifts that complicate production planning years in advance
  • 03Houston's selection reflects industrial capacity and workforce depth, positioning the region as a biomanufacturing corridor and creating long-term hiring demand in engineering, quality control, and skilled trades

Sep 21, 2026

Waiting for perfectly clean data is stalling healthcare AI, not protecting it

Healthcare organizations often delay AI initiatives waiting for perfectly clean data, but this assumption no longer holds: reliable subsets and synthetic data allow projects to start now while data work continues in parallel. Success requires starting with business outcomes rather than technology capabilities, and embedding governance in product strategy before implementation, not after.

  • 01Waiting for 100% clean data is effectively a decision never to start; hospital AI projects can begin on reliable data subsets while quality work continues in parallel.
  • 02Frame AI decisions around business outcomes (revenue growth, cost reduction, competitive advantage, new products, or ecosystem influence) rather than asking what AI can do.
  • 03Governance should be part of product strategy before design or purchase, especially as agentic AI takes actions—such as handling many revenue-cycle denials—while routing the rest to humans.

Sep 21, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512